Mattresses company Purple Innovation's Q3 revenue misses expectations

Reuters
11/05
Mattresses company <a href="https://laohu8.com/S/PRPL">Purple Innovation</a>'s Q3 revenue misses expectations

Overview

  • Purple Innovation Q3 2025 revenue missed analyst expectations despite slight year-over-year growth

  • Company reports improved net loss and positive adjusted EBITDA, reflecting profitability turnaround

  • Rejuvenate 2.0 and Mattress Firm expansion drive product and brand momentum

Outlook

  • Company maintains 2025 revenue guidance of $465 mln to $485 mln

  • Purple Innovation expects 2025 adjusted EBITDA of breakeven to $10 mln

  • Company cites Rejuvenate 2.0 and Mattress Firm partnership as growth drivers

Result Drivers

  • REJUVENATE 2.0 - Success of Rejuvenate 2.0 product line contributed to product and brand momentum

  • MATTRESS FIRM EXPANSION - Expansion of Mattress Firm partnership supported growth in premium segment

  • RESTRUCTURING BENEFITS - Completion of restructuring program led to cost savings and improved gross margins

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$118.76 mln

$123.20 mln (5 Analysts)

Q3 Net Income

-$11.74 mln

Q3 Gross Profit

$50.85 mln

Q3 Operating Expenses

$62.97 mln

Q3 Operating Income

-$12.12 mln

Q3 Pretax Profit

-$11.69 mln

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the home furnishings peer group is "buy."

  • Wall Street's median 12-month price target for Purple Innovation Inc is $3.30, about 75.8% above its November 3 closing price of $0.80

Press Release: ID:nPn5wQzf3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10